Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale
Go back to Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 159.76 -2.95 (1.81%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $162.71 | 52 Week High | $58.46 | |||
| Open | $162.04 | 52 Week Low | $31.25 | |||
| Day High | $162.97 | P/E | N/A | |||
| Day Low | $159.44 | EPS | $-0.69 | |||
| Volume | 1,055,121 | |||||
